Assessment of hearing loss in multi-drug resistant tuberculosis (MDR-TB) patients undergoing Aminoglycoside treatment

Nizamuddin, Sheikh; Khan, Farhan; Khan, Abdur Rehman; Kamaal, Chand Miyan

doi:10.18203/2320-6012.ijrms20150261

Cited by 8 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The poor thresholds reported in this study were all bilateral and evident in the high frequencies, which is consistent with findings by Sagwa et al [ 26 ], Nizamuddin et al [ 40 ], Sharma et al [ 41 ], and Tiwari et al [ 42 ]. These studies concluded that ototoxic hearing loss is bilateral and is evident in the high frequencies.…”

Section: Discussionsupporting

confidence: 93%

Aminoglycoside Therapy for Tuberculosis: Evidence for Ototoxicity among Tuberculosis Patients in Ghana

et al. 2022

View full text Add to dashboard Cite

Background: Hearing impairment (HI) is a major problem in Ghana; however, the few attempts at shedding light on its causes appear to overlook the adverse effects of some medications—a gap that this study sought to fill. Aminoglycoside therapy for tuberculosis (TB) treatment is one of these medications. Aim: The aim of this study was to establish the potential of aminoglycoside as a cause of hearing impairment among patients on anti-TB treatment. Method: This was a case–control study, involving patients receiving treatment for TB with aminoglycoside at the chest clinic of the Tema General Hospital and a control group of age- and gender-matched healthy volunteers. A structured questionnaire was administered to obtain the demographic data and case history of the participants. The hearing sensitivity of the participants was assessed using conventional pure tone audiometry and transient evoked otoacoustic emission tests. Results: A hearing loss prevalence of 20% (12/60) was found among patients receiving treatment for TB, with the intensity of impairment ranging from mild to severe. Hearing thresholds of patients receiving anti-TB medications were significantly elevated (p < 0.05) in comparison to the thresholds of the control group, especially at the high frequencies. Conclusion: This study shows that aminoglycoside therapy for tuberculosis may contribute to hearing impairment among tuberculosis patients in Ghana. Audiological management of these patients should therefore be an essential part of their therapeutic treatment plan.

show abstract

Section: Discussionsupporting

confidence: 93%

Aminoglycoside Therapy for Tuberculosis: Evidence for Ototoxicity among Tuberculosis Patients in Ghana

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Ototoksisitas dan nefrotoksisitas telah diketahui berhubungan dengan pemberian aminoglikosida, dimana ototoksik merupakan efek toksisitas utama dan biasanya bersifat permanen. 3 Efek ototoksik dari obat golongan aminoglikosida diperkirakan terjadi pada 3-13% dari pasien. Gejala ototoksik pada koklea yang muncul bisa berupa gangguan/ penurunan pendengaran dan tinitus.…”

Section: Pendahuluanunclassified

“…Insiden tuberkulosis yang lebih tinggi pada negara berkembang, menjadikan pasien-pasien memiliki ketahanan yang lebih buruk pada reaksi obat dan tingkat resistensi kuman yang lebih tinggi, sehingga risiko terjadinya ototoksisitas lebih tinggi pada area-area yang penduduknya memiliki sosio-ekonomi rendah. 3 Pada pemeriksaan audiometri nada murni sebagai data awal penelitian didapati 9 subjek dengan fungsi pendengaran normal (75%). Faktor yang dapat memengaruhi fungsi pendengaran subjek yang didapati pada penelitian ini adalah status diabetes, merokok, dan usia.…”

Section: Diskusiunclassified

Hubungan Pemberian Kanamisin dengan Kejadian Ototoksik pada Penderita Tuberkulosis Multi Drug Resistance

Wahyudin

Indrasworo

Wahyudiono

2019

Oto Rhino Laryn Indones

View full text Add to dashboard Cite

Latar Belakang: Ototoksik merupakan salah satu efek samping kanamisin yang sulit dihindari. Ototoksisitas kanamisin ditandai dengan gangguan pendengaran sensorineural yang progresif dan sering irreversible dimulai dari frekuensi lebih dari 8000 Hz yang akhirnya akan mengenai frekuensi yang lebih rendah jika terapi dilanjutkan. Tujuan: Penelitian ini bertujuan untuk mengetahui pengaruh pemberian kanamisin pada pasien tuberkulosis multi drug resistance (TB MDR) terhadap munculnya ototoksik dengan pemeriksaan audiometri. Metode: Penelitian observasional longitudinal dengan pendekatan cohort ini mengevaluasi fungsi pendengaran sebelum dan setelah pemberian kanamisin pada pasien TB MDR. Pemeriksaan fungsi pendengaran menggunakan audiometri nada murni. Kanamisin adalah aminoglikosida pilihan pada pasien dengan TB MDR yang akan diberikan secara injeksi intramuskular. Hasil: Uji Friedman’s menunjukkan ditemukan perubahan yang bermakna pada hasil pengukuran audiometri pada frekuensi tinggi antara pasca injeksi kanamisin bulan pertama, kedua, hingga kelima dengan hasil pengukuran sebelum terapi (p>0,05). Diagnosis ototoksisitas menggunakan kriteria American-Speech-Language-Hearing-Association (ASHA) dapat dideteksi sejak bulan pertama pemberian kanamisin (25%). Kesimpulan: Ada hubungan antara kejadian ototoksik dengan pemberian kanamisin pada penderita TB MDR. Telah terjadi ototoksisitas sejak injeksi kanamisin bulan pertama yang dideteksi dengan menggunakan pemeriksaan audiometri, dan bermakna secara statistik. Introduction: Ototoxicity is one of common side effects of kanamycin which is hard to avoid. Ototoxicity can be detected by a progressive and irreversible high frequency sensorineural hearing loss that can further affect low frequency if the therapy is continued. Kanamycin is the drug-of-choice for TB MDR through intramuscular (IM) injection. Purpose: This study aims to determine whether kanamycin can cause ototoxicity in patient with MDR TB by using audiometry examination. Method: An observational longitudinal study with cohort design, evaluating patient’s hearing threshold before and after kanamycin IM injection once per month using pure tone audiometry. Result: A significant alteration in high pitch before and after injection of kanamycin was revealed with Friedman’s test (p<0.05) for hearing threshold using pure tone audiometry. Furthermore, using American Speech-Language-Hearing Association (ASHA) the diagnosis of ototoxicity can be established since the first month of kanamycin injection in 25% of the subjects, and also 25% in the second month of injection. Conclusion: There is a significant connection between ototoxicity with kanamycin injection in MDR TB patients, statistically proven. The ototoxicity can happen since the first month of injection, which can be detected using pure tone audiometry.

show abstract

“…37,38 Deteksi penurunan ambang dengar pada frekuensi tinggi sebagai indikator yang paling efektif dalam menilai terjadinya ototoksik, terutama bila menggunakan frekuensi ultratinggi (>8000kHz) dan atau otoacoustic emission (OAE). 10,35 Audiometri berkala dapat mencegah atau mengetahui awitan terjadinya ototoksik sebelum menjadi sebuah kelainan yang semakin berat dan menetap. 15 Deteksi dini ototoksik pada frekuensi tinggi dan diikuti dengan tatalaksana yang baik akan menjaga kemampuan komunikasi dan kualitas hidup pasien.…”

unclassified

The Prevalens of Ototoxicity in Drug Resistance Tuberculosis Patients and The Associated Factors at Persahabatan General Central Hospital

et al. 2019

View full text Add to dashboard Cite

Background: The treatment of drug resistance tuberculosis needs second line injection antituberculosis drug that associated with irreversible ototoxic. The aim of this study is to know the prevalence of ototoxicity in tuberculosis drug resistance patients and the contributing factors. Methods: This is a cross sectional study among drug resistance TB patients who receive kanamysin or capreomycin as a part of drug regimen during intensive phase in January to September 2017 at Persahabatan hospital. Ototoxic defined according to American Speech Language and Hearing Association (ASHA) 1994 criteria by comparing baseline audiometric examination before treatment with current result. Results: Seventy-two patients were included in this study. The prevalence of ototoxicity was found in 34 patients (47,2%). Ototoxic found in 5 subjects (14,7%) during the first month of treatment and 19 subjects (56%) without hearing disturbance complain. Ototoxic in kanamisin group (47,9%) is more frequent compared with capreomisin (36,8%). Ototoxicity was associated with age, the risk increases 5% every 1 year older p=0,029 aOR:1,050 IK95% (1,005-1,096). The prevalences of ototoxicity are higher in diabetes and increasing serum creatinin patients but statistically not significance. Sex, body mass index, the history of using injectable antiTB drug, HIV status and total dosis were not associated with ototoxicity. Conclusion: Ototoxicity is common in intensive phase of drug resistance tuberculosis treatment. Further study needed to determine the association of contributing factors. (J Respir Indo. 2019; 39(3):180-95)

show abstract

Assessment of hearing loss in multi-drug resistant tuberculosis (MDR-TB) patients undergoing Aminoglycoside treatment

Cited by 8 publications

References 14 publications

Aminoglycoside Therapy for Tuberculosis: Evidence for Ototoxicity among Tuberculosis Patients in Ghana

Aminoglycoside Therapy for Tuberculosis: Evidence for Ototoxicity among Tuberculosis Patients in Ghana

Hubungan Pemberian Kanamisin dengan Kejadian Ototoksik pada Penderita Tuberkulosis Multi Drug Resistance

The Prevalens of Ototoxicity in Drug Resistance Tuberculosis Patients and The Associated Factors at Persahabatan General Central Hospital

Contact Info

Product

Resources

About